Edition:
India

WAVE Life Sciences Ltd (WVE.OQ)

WVE.OQ on NASDAQ Stock Exchange Global Market

33.95USD
22 Jun 2018
Change (% chg)

$-1.48 (-4.16%)
Prev Close
$35.42
Open
$35.45
Day's High
$35.45
Day's Low
$32.25
Volume
687,646
Avg. Vol
64,824
52-wk High
$55.95
52-wk Low
$15.15

Latest Key Developments (Source: Significant Developments)

Wave Life Sciences Reports Data From Preclinical Studies Testing WVE-3972-01
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Wave Life Sciences Ltd ::WAVE LIFE SCIENCES - ANNOUNCED DATA FROM PRECLINICAL STUDIES OF WVE-3972-01 FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA.WAVE LIFE SCIENCES - WVE-3972-01 DEMONSTRATED SUBSTANTIAL REDUCTION IN DISEASE-ASSOCIATED BIOMARKERS & SUPERIOR POTENCY TO STEREORANDOM OLIGONUCLEOTIDES.WAVE LIFE SCIENCES LTD - CO INTENDS TO INITIATE CLINICAL TRIALS OF WVE-3972-01 IN ALS AND FTD IN Q4 2018.  Full Article

Wave Life Sciences Q3 net loss of $26.1 million
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Wave Life Sciences Ltd ::Wave Life Sciences reports third quarter 2017 financial results and provides business update.Wave Life Sciences Ltd - ‍ Wave reported a net loss of $26.1 million for Q3 of 2017, as compared to a net loss of $17.5 million for Q3 of 2016​.Wave Life Sciences Ltd - qtrly loss per share $0.94‍​.Wave Life Sciences -‍ expects capital resources available, anticipated milestone payments to be sufficient to fund expenses, capex needs into mid-2019​.  Full Article

Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Wave Life Sciences Ltd :Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy (DMD).Wave Life Sciences Ltd - ‍data from phase 1 trial for WVE-210201 are expected in Q3 2018​.  Full Article

Wave Life Sciences appoints chief financial officer
Wednesday, 17 Aug 2016 

Wave Life Sciences Ltd : Wave life sciences appoints Keith Regnante as chief financial officer .Says prior to joining wave, Regnate was a vice president of finance at Shire.  Full Article

BRIEF-Wave Life Sciences Reports Qtrly Loss Per Share $1.26

* WAVE LIFE SCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE